Novo Nordisk stock gains as oral Wegovy launches in Germany

Novo Nordisk stock is trading higher after the company confirmed the September 1, 2026 launch of its oral Wegovy weight-loss pill in Germany, while Q2 2026 figures show strong profitability in its obesity and diabetes franchise.

Novo Nordisk stock is trading firmer after the Danish pharmaceutical group (ISIN DK0062498333) confirmed the launch of its oral Wegovy weight-loss tablet in Germany on September 1, 2026, adding a new GLP-1 obesity product to its portfolio in a key European market. According to analyst data compiled by Yahoo Finance, Novo Nordisk generated revenue of 78.49 billion Danish kroner in Q2 2026 with earnings of 20.99 billion kroner, implying a profit margin of 26.74% for the quarter.

Oral Wegovy launch in Germany

Germany has become the first country in the European Union to receive Novo Nordisk's oral version of Wegovy, as the company confirmed the launch on September 1, 2026. The tablet formulation contains semaglutide, the same active ingredient as the injectable Wegovy, and offers an oral alternative for eligible patients seeking medical treatment for obesity, according to a report by EUReflect.

The German market has been selected as the first European launch market for the Wegovy pill, highlighting the strategic importance of Germany within Novo Nordisk's obesity franchise. For DACH-region investors, Germany's early access to the oral Wegovy treatment underscores the local relevance of Novo Nordisk's pipeline, as obesity medicines increasingly shape pharmaceutical growth in Europe.

Profitability and consensus for 2026

Beyond the product launch, Novo Nordisk's latest quarterly numbers show a highly profitable business. In Q2 2026, revenue of 78.49 billion Danish kroner translated into earnings of 20.99 billion kroner, resulting in a profit margin of 26.74%, as summarized in the same analyst overview. Compared with the prior year trend indicated in the consensus table, sales growth for the current full year 2026 is estimated at negative 3.11%, while the 2027 estimate points to a modest 1.53% increase, signalling a normalization phase after the boom phase of GLP-1 launches.

The same consensus grid lists estimated sales growth of negative 2.76% for the current quarter ending September 2026 and negative 6.54% for the quarter ending December 2026, suggesting that analysts expect slower reported growth in the near term. However, the combination of a still robust 26.74% profit margin in Q2 2026 and a 2027 sales growth estimate back in positive territory indicates that the market still prices Novo Nordisk as a structurally profitable obesity and diabetes specialist rather than a short-lived momentum story.

GLP-1 competition and strategic collaborations

Competition in obesity therapies remains intense. A recent article on Pfizer's pipeline strategy highlights that current popular GLP-1 weight-loss treatments include Eli Lilly's Zepbound and Novo Nordisk's Wegovy, both administered as weekly injections. As new entrants prepare late-stage obesity candidates, Novo Nordisk is responding by broadening its pipeline and formulations.

In parallel, Denmark-based Novo Nordisk has entered a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines targeting obesity, diabetes and associated metabolic diseases, as reported by European Biotechnology. This collaboration sits alongside the oral Wegovy tablet launch and underlines Novo Nordisk's focused strategy on making GLP-1 based therapies more convenient and accessible, including oral biologics.

Regionally, Novo Nordisk has also expanded its obesity line in markets such as South Africa. A report by Business Insider Africa notes that Wegovy, using semaglutide, was launched in South Africa in 2025, intensifying competition with Eli Lilly's Mounjaro in a weight-loss drug market valued at 187 million dollars. For investors, these launches show how Novo Nordisk leverages the same core molecule across geographies and indications.

Representative product: Wegovy obesity treatment

A central product in Novo Nordisk's growth story is Wegovy, a semaglutide-based medicine registered for chronic weight management. The oral Wegovy tablet now available in Germany from September 1, 2026 uses the same active ingredient and offers a less invasive administration route for obesity patients compared with weekly injections, according to the EUReflect coverage of the German launch. The injectable Wegovy had already been rolled out in multiple markets, including South Africa in 2025, helping to build a global franchise in obesity treatments.

Wegovy complements Novo Nordisk's broader diabetes portfolio, which includes insulins and GLP-1 analogues. At the same time, the company has announced that several legacy diabetes medicines, such as Levemir and Victoza, will be discontinued in French pharmacies by December 31, 2026 as part of an industrial reallocation, according to a detailed article by E-sante. This shift illustrates how Novo Nordisk is redirecting resources from older diabetes products towards newer GLP-1 based and obesity-oriented therapies like Wegovy.

Stock level and investor perspective

MarketBeat's latest overview of Novo Nordisk's American depositary shares on the New York Stock Exchange shows the stock at 47.45 dollars, up 0.68 dollars or 1.45% at the close on September 3, 2026, as cited in MarketBeat. This places the Novo Nordisk stock below its mid-2024 peak but supported by a profitable Q2 2026 and fresh product catalysts in the obesity franchise.

Novo Nordisk stock at a glance

• Company: Novo Nordisk A/S
• ISIN: DK0062498333
• Ticker: NVO
• Trading venue: NYSE (American depositary shares)
• Price (as of September 3, 2026, 03:58 PM): 47.45 USD
• Market capitalization: [value not specified in available sources]
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500